Hip and knee replacement surgery rates per 100,000 population by month and year in Ontario (1992–2002)

<p><b>Copyright information:</b></p><p>Taken from "Seasonality of service provision in hip and knee surgery: A possible contributor to waiting times? A time series analysis"</p><p>BMC Health Services Research 2006;6():22-22.</p><p>Published online 1 Mar 2006</p><p>PMCID:PMC1420281.</p><p>Copyright © 2006 Upshur et al; licensee BioMed Central Ltd.</p

Additional file 2: of An exploratory pilot study to assess self-perceived changes among social assistance recipients regarding employment prospects after receiving dental treatment

Table. Job-seeking Skills Self-efficacy (JSS) scale. (DOCX 58 kb

Hip and knee replacement surgery rates per 100,000 population aggregated by month in Ontario (1992–2002)

<p><b>Copyright information:</b></p><p>Taken from "Seasonality of service provision in hip and knee surgery: A possible contributor to waiting times? A time series analysis"</p><p>BMC Health Services Research 2006;6():22-22.</p><p>Published online 1 Mar 2006</p><p>PMCID:PMC1420281.</p><p>Copyright © 2006 Upshur et al; licensee BioMed Central Ltd.</p

Surgery and Patient Rates, stratified by gender (per 10,000 population).

<p>Surgery and Patient Rates, stratified by gender (per 10,000 population).</p

Additional file 1: of An exploratory pilot study to assess self-perceived changes among social assistance recipients regarding employment prospects after receiving dental treatment

Table. Oral Health Impact Profile -14 (OHIP-14) questionnaire. (DOCX 18 kb

Patient Surgery Rates, stratified by age (per 10,000 population).

<p>Patient Surgery Rates, stratified by age (per 10,000 population).</p

Characteristics of Carpal Tunnel Surgery Patients: All Surgeries between Jan 1 1993 and December 31 2009.

<p><b>Abbreviations:</b> N: Number; SD: Standard Deviation; NCS: Nerve Conduction Study; CTS: Carpal Tunnel Syndrome; OHIP: Ontario Health Insurance Plan.</p

Baseline Characteristics of Men Newly Prescribed Testosterone between April 1 2010 and March 31 2012.

<p>*Indicates a statistically significant difference (p-value<0.05) when comparing injectable to topical patient group.</p><p>**Indicates a statistically significant difference (p-value<0.05) when comparing oral to topical patient group.</p>‡<p>Cells suppressed due to small numbers to protect the privacy of patients.</p

Rate of Testosterone Use per 1,000 Men Eligible for Public Drug Coverage and Aged 65 and older.

<p><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0098003#pone-0098003-g001" target="_blank">Figure 1</a> depicts a steady 286% increase in testosterone use between 1997 and 2003, and a subsequent plateau in 2004 and 2005. In early 2006, the introduction of universal prescribing restrictions for TRT led to a 27.9% drop in total user rates within a 6 month period, driven by the decline of oral (p<0.01) and injectable (p<0.01), but not topical testosterone use. However, after this initial drop, total TRT use started to increase again and by the end of the study period (March 2012) TRT rates had reached a historical peak of 11.0 men per 1000 eligible population. This increase was largely driven by the use of topical testosterone products, while rates of oral and injectable use each fell 32% and 35% respectively after the universal restriction policy was implemented and remained at this new low.</p

High-Dose Opioid Prescribing and Opioid-Related Hospitalization: A Population-Based Study

<div><p>Aims</p><p>To examine the impact of national clinical practice guidelines and provincial drug policy interventions on prevalence of high-dose opioid prescribing and rates of hospitalization for opioid toxicity.</p><p>Design</p><p>Interventional time-series analysis.</p><p>Setting</p><p>Ontario, Canada, from 2003 to 2014.</p><p>Participants</p><p>Ontario Drug Benefit (ODB) beneficiaries aged 15 to 64 years from 2003 to 2014.</p><p>Interventions</p><p>Publication of Canadian clinical practice guidelines for use of opioids in chronic non-cancer pain (May 2010) and implementation of Ontario’s Narcotics Safety and Awareness Act (NSAA; November 2011).</p><p>Measurements</p><p>Three outcomes were explored: the rate of opioid use among ODB beneficiaries, the prevalence of opioid prescriptions exceeding 200 mg and 400 mg morphine equivalents per day, and rates of opioid-related emergency department visits and hospital admissions.</p><p>Findings</p><p>Over the 12 year study period, the rate of opioid use declined 15.2%, from 2764 to 2342 users per 10,000 ODB eligible persons. The rate of opioid use was significantly impacted by the Canadian clinical practice guidelines (p-value = .03) which led to a decline in use, but no impact was observed by the enactment of the NSAA (p-value = .43). Among opioid users, the prevalence of high-dose prescribing doubled (from 4.2% to 8.7%) over the study period. By 2014, 40.9% of recipients of long-acting opioids exceeded daily doses of 200 mg morphine or equivalent, including 55.8% of long-acting oxycodone users and 76.3% of transdermal fentanyl users. Moreover, in the last period, 18.7% of long-acting opioid users exceeded daily doses of 400 mg morphine or equivalent. Rates of opioid-related emergency department visits and hospital admissions increased 55.0% over the study period from 9.0 to 14.0 per 10,000 ODB beneficiaries from 2003 to 2013. This rate was not significantly impacted by the Canadian clinical practice guidelines (p-value = .68) or enactment of the NSAA (p-value = .59).</p><p>Conclusions</p><p>Although the Canadian clinical practice guidelines for use of opioids in chronic non-cancer pain led to a decline in opioid prescribing rates among ODB beneficiaries these guidelines and subsequent Ontario legislation did not result in a significant change in rates of opioid-related hospitalizations. Given the prevalence of high dose opioid prescribing in this population, this suggests that improved strategies and programs for the safe prescribing of long-acting opioids are needed.</p></div